AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04601545 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Pulmonary rehabilitation
Description: Three weeks of pulmonary rehabilitation conducted in an outpatient care facility:~* 5- time a week for 30 minutes a specific respiratory exercises- relaxation exercises for breathing muscles, exercises to increase breathing, prolonged exhalation exercise, chest percussion~* 5- time a week for 20-30 min training on a cycle ergometer - until the Heart Rate reaches 60% of the HRmax~* 5- time a week for 30 minutes a fitness and respiratory exercises - coordination and balance exercises, stretching exercises~* relaxation by Schultz Autogenic Training. The technique involves the daily practice of sessions that last around 15 minutes. During each session, the practitioner repeats a set of visualisations that induce a state of relaxation.
Study NCT02102854 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rATG
Description: Infusion of horse or rabbit-derived antibodies against human T cells, used to prevent \& treat acute rejection in organ transplantation
Study NCT02102854 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: rATG
Description: Infusion of horse or rabbit-derived antibodies against human T cells, used to prevent \& treat acute rejection in organ transplantation
Study NCT04443972 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PD VitalOs cement®
Description: PD VitalOs cement®\* is a synthetic bone grafting cement designed for bone void filling and bone regeneration in dental surgery
Study NCT04443972 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hydroxyapatite bone graft
Description: a bioceramic bone substitute, providing a scaffold for bone deposition
Study NCT04443972 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: biodegardable collagen membrane
Description: provide efficacious barriers that were interposed between the flap and root surface.
Study NCT02198937 — intervention group
Intervention type: OTHER
Intervention: Blood sample
Study NCT04601545 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Virtual therapeutic support
Description: 8 sessions of VR therapy (each of them 20 minutes long). As a virtual reality source, VR Tier One device (Stolgraf®) were used. Thanks to using head mounted display and the phenomenon of total immersion VR therapy provides an intense visual, auditory and kinesthetic stimulation. It can have a calming and mood-improving effect or help the patients recognize their psychological resources and motivate to the rehabilitation process. In the virtual therapeutic garden there are a rich set of symbols and metaphors based on Ericksonian Psychotherapy approach. The most important is the Garden of Revival which symbolizes the patient's health. It used to be full of life and energy, now it is neglected, requires work to be revived. In the therapeutic process day by day, the therapist tells the patient a symbolic story about his/her situation.~By performing tasks in the virtual garden, the patient becomes an active participant of the therapeutic process and sees the effects his/her work.
Study NCT03708094 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: molecular diagnosis
Description: whole exome sequencing and data analysis to elucidating molecular diagnosis
Study NCT01956474 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Theralight crosslinking and Riboflavin
Description: Corneal Collagen cross linking with UV light and riboflavin
Study NCT02625610 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-Fluorouracil
Description: Induction Phase: 5-Fluorouracil was administered at a dose of 2600 mg/m\^2 IV continuous infusion over 24 hours on Day 1 (or) 5-FU at 400 mg/m\^2 IV push on Day 1 and 2400 mg/m\^2 IV continuous infusion over 46-48 hours (Days 1 and 2) along with oxaliplatin and leucovorin every 2 weeks up to 12 weeks. Maintenance Phase: Participants were continued the same regimen of chemotherapy as they received during the Induction Phase until disease progression, significant clinical deterioration, unacceptable toxicity, or discontinuation.
Study NCT02625610 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin
Description: Induction Phase: Leucovorin was administered at a dose of 200 mg/m\^2 IV (or) Leucovorin 400 mg/m\^2 IV on Day 1 along with oxaliplatin and 5-FU every 2 weeks up to 12 weeks.~Maintenance Phase: Participants were continued the same regimen of chemotherapy as they received during the Induction Phase until disease progression, significant clinical deterioration, unacceptable toxicity, or discontinuation.
Study NCT02286232 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Stretching exercise
Description: This program begins with 10 stretches/exercises over 15 minutes on the initial class and incrementally increases by 1 stretch/exercise each session for a total of 21 stretches/exercises over 30 minutes on the 12th session. The program is designed to stretch/exercise the major muscle groups, emphasizing the neck and arms, trunk, and legs. In addition to the stretches, each class will include breathing exercises and guided imagery for relaxation. Classes will be taught by Physical Therapists who are trained to lead classes through the protocol.
Study NCT02286232 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Self-care book
Description: The Back Pain Helpbook which provides information on the causes of back pain and advice on exercising, making appropriate lifestyle modifications, and managing flare-ups.
Study NCT01402739 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Point of Care Coagulation Monitoring Guided Transfusion Algorithm
Description: (thromboelastometry, aggregometry, blood gas analysis)
Study NCT01402739 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: standard coagulation monitoring guided transfusion algorithm
Description: aPTT, ACT, platelet count, hemoglobin, fibrinogen
Study NCT01248949 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEDI3617
Description: Participants will receive MEDI3617 via IV infusion in each cycle until unacceptable toxicity, initiation of alternative anticancer treatment, documented disease progression, or other reasons.
Study NCT03326011 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Samsung Hip Assist v1
Description: All subjects receive gait training 3 times per week for 8 weeks for 24 training sessions. Each session is directed by a licensed physical therapist and lasted 60 min including rest period of 10 min. Brain activity and gait assessment is performed at visits 0 (baseline), 24 (post-test), and at 3 months (follow-up) after training.
Study NCT00678210 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CP-690,550
Description: tablets, 2 mg BID for 12 weeks
Study NCT00678210 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CP-690,550
Description: tablets, 5 mg BID for 12 weeks
Study NCT00678210 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CP-690,550
Description: tablets, 15 mg BID for 12 weeks
Study NCT00678210 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: tablets, BID for 12 weeks
Study NCT01248949 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Participants will receive bevacizumab via IV infusion in each cycle until unacceptable toxicity, initiation of alternative anticancer treatment, documented disease progression, or other reasons.
Study NCT01248949 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Participants will receive paclitaxel via IV infusion in each cycle until unacceptable toxicity, documented disease progression, or other reasons.
Study NCT01248949 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Participants will receive carboplatin via IV infusion in each cycle until unacceptable toxicity, documentation of disease progression, or other reasons.
Study NCT01128946 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NaF
Description: Fluoride toothpaste containing sodium fluoride as 1450 parts per million (ppm) F, 675 ppmF, 450 ppmF, 350ppmF.
Study NCT01128946 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NaF
Description: Fluoride toothpaste containing sodium fluoride as 1450 parts per million (ppm) F, 675 ppmF, 450 ppmF, 350ppmF.
Study NCT01128946 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SnF
Description: Fluoride toothpaste containing stannous fluoride (1100 ppmF)
Study NCT01128946 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NaMFP
Description: Fluoride toothpaste containing sodium monofluorophosphate (1000 ppmF)
Study NCT03998969 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pantoprazole
Description: Pantoprazole 40mg tablet
Study NCT03998969 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pantoprazole
Description: Pantoprazole 40mg tablet
Study NCT01838642 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ponatinib
Description: Ponatinib tablets will be administered orally, continually, once daily at a dose of 30 mg. A cycle of ponatinib is defined as 28 consecutive days starting with the first day of the treatment cycle. Treatment will be administered primarily in an outpatient setting.
Study NCT03998969 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DA-5204
Description: DA-5204 tablet
Study NCT03998969 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Film-coated tablet manufactured to mimic DA-5204
Study NCT03941626 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CAR-T/TCR-T cells immunotherapy
Description: According to tumor burden and other conditions, patients will be treated with cyclophosphamide or fludarabine,then,CAR-T cells will be infused 48-72 hours later.
Study NCT01339897 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5 mg/N6022
Description: Intravenous formulation, given at doses of 5 mg once each day over 7 days.
Study NCT01339897 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Same administration procedures as active
Study NCT01339897 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 10mg/N6022
Description: Intravenous formulation given at doses of 10 mg once each day over 7 days.
Study NCT01339897 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 20mg/N6022
Description: Intravenous formulation given at doses of 20 mg once each day over 7 days.
Study NCT01884272 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: lesinurad 400 mg
Study NCT01884272 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lesinurad 400 mg
Study NCT01884272 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: naproxen 250 mg
Study NCT01884272 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: indomethacin 25 mg
Study NCT04569981 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Climbing
Description: The patients in the Climbing Group (CG) followed a 12-weeks long climbing trainings course in small groups of 3-4 participants with a certified climbing instructor.
Study NCT04569981 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Unsupervised activity group
Description: The patients in the unsupervised activity group (UAG) received education European physiotherapy guidelines for physical activity recommended by the WHO of recommended activity and followed their self-selected activities over 12 weeks.
Study NCT00862056 — intervention group
Intervention type: PROCEDURE
Intervention: Cardiac CT
Description: All participants will undergo a coronary artery CT angiogram with contrast.
Study NCT03245775 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: iChoose
Description: 12 bi-weekly sessions \& 24 IVR calls/12 months, 24 physical activity sessions over 6 months; delivers intervention to parents and children only
Study NCT03245775 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Family Connections
Description: 2 in-person sessions spaced one week apart \& 10 IVR calls/6 months, promotes physical activity but does not include structured exercise sessions; delivers intervention to parents only
Study NCT00406679 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paracetamol (acetaminophen) solution experimental
Description: 1 gm IV
Study NCT00406679 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: paracetamol (acetaminophen) solution commercial
Description: 1 gm IV
Study NCT00406679 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: equivalent volume IV 0.9% sodium chloride (equivalent volume)
Study NCT03821610 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fludarabine
Description: IV
Study NCT03821610 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Melphalan
Description: IV
Study NCT03821610 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alemtuzumab
Description: IV
Study NCT03821610 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Alemtuzumab
Description: IV
Study NCT03821610 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: IV
Study NCT03821610 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mesna
Description: IV
Study NCT03821610 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Total Body Irradiation (8Gy)
Description: TBI (8Gy)
Study NCT00766051 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: The intervention group: Neurophysiologically Based Occupational Therapy Intervention (NBOTI)
Description: This study included a pre-feeding, feeding, and postural-respiratory protocol, given per the attending physician's order. The interventions were given daily when possible, and the infants FiO2 and heart rate, along with stress behaviors, were monitored prior to, during, and after the NBOTI. The intervention included parent education for feeding, handling, and interaction with their infant, along with nursing training during the feeding session. The occupational therapy investigator partnered with the parents and when the parents were not available, she partnered with the nursing staff.
Study NCT04152408 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FiberSense System
Description: FiberSense system, a novel CGM system, based on a fiber-optical sensor placed through the dermis of the patient.
Study NCT02625610 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Induction Phase: Capecitabine was administered at a dose of 1000 mg/m\^2 twice daily for 2 weeks followed by a 1-week rest period given every 3 weeks along with oxaliplatin up to 12 weeks.~Maintenance Phase: Participants were continued the same regimen of chemotherapy as they received during the Induction Phase every 3 weeks until disease progression, significant clinical deterioration, unacceptable toxicity, or discontinuation.
Study NCT02625610 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Best supportive care
Description: Treatment administered with the intent to maximize Quality of Life (QoL) without a specific antineoplastic regimen. These may include for example antibiotics, analgesics, antiemetics, thoracentesis, paracentesis, blood transfusions, nutritional support (including jejunostomy), and focal external-beam radiation for control of pain, cough, dyspnea, or bleeding. Best supportive care were administered per institutional guidelines and participants were visit the clinic every 3 weeks.
Study NCT02625610 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Induction Phase: Oxaliplatin will be administered at a dose of 85 mg per square meter (mg/m\^2) as a continuous intravenous (IV) infusion on Day 1 along with leucovorin followed by 5-Fluorouracil every 2 weeks up to 12 weeks (or) Oxaliplatin at 130 mg/m\^2 IV on Day 1 along with capecitabine twice daily for 2 weeks followed by a 1-week rest period given every 3 weeks up to 12 weeks.
Study NCT02625610 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-Fluorouracil
Description: Induction Phase: 5-Fluorouracil will be administered at a dose of 2600 mg/m\^2 IV continuous infusion over 24 hours on Day 1 (or) 5-FU at 400 mg/m\^2 IV push on Day 1 and 2400 mg/m\^2 IV continuous infusion over 46-48 hours (Days 1 and 2) along with oxaliplatin and leucovorin every 2 weeks up to 12 weeks.
Study NCT02625610 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin
Description: Induction Phase: Leucovorin will be administered at a dose of 200 mg/m\^2 IV (or) Leucovorin 400 mg/m\^2 IV on Day 1 along with oxaliplatin and 5-FU every 2 weeks up to 12 weeks.
Study NCT01839812 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Cosyntropin
Description: A cosyntropin stimulation test is administered to each patient at 3 time points during the study to evaluate adrenal response.
Study NCT03302247 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Monoclonal antibody against non small cell lung cancer
Study NCT03302247 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab+Gemcitabine
Description: Gemcitabine is added to the Nivolumab treatment
Study NCT03062111 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ProTouch Laser Enucleation of Prostate (LEP)
Description: Laser enucleation of the prostate is a standard form of treatment for BPH used widely. The ProTouch laser is established to be safe and is newer than the holmium laser.
Study NCT03062111 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Transurethral Resection of Prostate (TURP)
Description: TURP has been considered a gold standard for treatment of BPH in which rigid resectoscopes with bipolar cautery are used to endoscopically resect prostatic tissue.
Study NCT02371603 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1278863 25 mg Tablet
Description: A round, biconvex, white film coated tablet to be taken orally in the fasted state in the morning
Study NCT02371603 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pioglitazone 15 mg Tablet
Description: White to off-white, round, convex, non scored tablet with ACTOS on one side, and 15 on the other, to be taken orally in the fasted state in the morning
Study NCT02371603 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin 10 mg Tablet
Description: Pink, round, biconvex, coated tablets. Debossed CRESTOR and 10 on one side, to be taken orally in the fasted state in the morning
Study NCT03127891 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: pranayama yoga
Description: providing short term pranayama yoga for 5 sessions before surgery patients under going cardiac surgery.
Study NCT03127891 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: control group
Description: no intervention should be given to patients allocated to this group
Study NCT04010721 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Experiment 1
Description: Stimulation of one electrode at a time
Study NCT04010721 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Experiment 2:
Description: Stimulation in groups of 4, 8 and 12 electrodes
Study NCT02625610 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Induction Phase: Capecitabine will be administered at a dose of 1000 mg/m\^2 twice daily for 2 weeks followed by a 1-week rest period given every 3 weeks along with oxaliplatin up to 12 weeks.
Study NCT03089229 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HAT01H Cream
Description: HAT01H Cream will be applied twice daily. The research team will provide instructions for the correct application of the treatment. If a lesion disappears, patients will continue applying the cream twice daily to the area. No additional creams, lotions or soaps other than provided test products will be allowed throughout the duration of the study.
Study NCT03089229 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle Cream
Description: Vehicle Cream will be applied twice daily. The research team will provide instructions for the correct application of the treatment. If a lesion disappears, patients will continue applying the cream twice daily to the area. No additional creams, lotions or soaps other than provided test products will be allowed throughout the duration of the study.
Study NCT00389909 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxapram
Description: Dosing comparison between fixed scheduled and sex related dosage.~Dosing related to weight only versus chart taking into account weight, age and gender.
Study NCT02789761 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: High-flavanol milk choocolate
Study NCT02789761 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Low-flavanol milk chocolate
Study NCT03458351 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Remote ischemic preconditioning
Description: Four cycles of 5 min of ischemia, which is induced by a blood pressure cuff in the upper arm inflated to 200 mmHg, followed by 5 min of reperfusion, during which the cuff is deflated.
Study NCT03458351 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham control
Description: The same blood pressure cuff is placed around the upper arm, but the cuff is inflated to 10 mm Hg and ischemic preconditioning is not induced.
Study NCT03622294 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bella Blankets protective coverlets
Description: Bella Blankets protective coverlets is a Class II 510(k) Cleared (2008) single-use, adhering, non-woven fabric sheet applied to the mammography equipment receptor plate to provide a more comfortable mammogram.